Role of PD‐L1 Expression in Non‐Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
Open accessThe DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.
Abstract
Background: The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Therefore, we examined this relationship and also compare PD-L1 expression levels with Ki-67, p63 and TTF-1. Methods: 866 samples of NSCLCs were used to prepare tissue microarrays (TMAs) on which immunohistochemical (IHC) reactions were performed. Changes in the level of CD274 (PD-L1) gene expression in 62 NSCLC tumors were tested in relation to 14 normal lung tissues by real-time PCR reactions (RT-PCR). Results: PD-L1 expression was observed in 32.6% of NSCLCs. PD-L1 expression was increased in higher malignancy grades (G) (p < 0.0001) and in higher lymph node status (pN) (p = 0.0428). The patients with low PD-L1 expression had longer overall survival compared to the group with high expression (p = 0.0332) in adenocarcinoma (AC) only. Conclusions: PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in NSCLC, predominantly in the AC group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, anti‐PD‐1/PD‐L1 antibodies can promote T cell activation and enhance anti‐tumor immunity by blocking the interaction between PD‐1 and PD‐L1/PD‐L2 [270, 271].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [271]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some tumors express PD‐L1, which contributes to immune evasion by inhibiting cytotoxic responses.”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [271]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 1×
“The estimation of PD-L1 expression was performed using the Tumor Proportion Score (TPS) that is applied routinely in diagnostic settings [4,27,28].”
MethodLung Cancer: Epidemiology, Etiology, and Prevention
Dela Cruz, C. S., Tanoue, L. T., & Matthay, R. A. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.09.001 · Cited by 2,484 · cited 1×
“According to the American Cancer Society, the number of deaths from lung cancer is higher than the number of deaths caused by breast, colon and prostate cancers [1].”
BackgroundRemmele, W., & Stegner, H.-E. (1987) · PubMed · Cited by 1,976
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J., Chirieac, L. R., D'Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,303
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791 · cited 1×
“The first effect is inhibition of interleukin 2 (IL-2) synthesis [8].”
BackgroundProgrammed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755 · cited 1×
“In our cohort, involving a Western population, the incidence was lower, which is similar to other studies on this ethnic group [12,16,24] Another explanation for diverse expression of PD-L1 in NSCLC may be related to the use of different scoring methods and cut-off levels for evaluation.”
ResultKonishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678
Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 645
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
D'Incecco, A., Andreozzi, M., Ludovini, V, Rossi, E., Capodanno, A., Landi, L., Tibaldi, C., Minuti, G., Salvini, J., Coppi, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.555 · Cited by 593
Mu, C.-Y., Huang, J.-A., Chen, Y., Chen, C., & Zhang, X.-G. (2011) · Medical Oncology · doi:10.1007/s12032-010-9515-2 · Cited by 577
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Cooper, W. A., Tran, T., Vilain, R. E., Madore, J., Selinger, C. I., Kohonen-Corish, M., Yip, P., Yu, B., O’Toole, S. A., McCaughan, B. C., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.05.007 · Cited by 294 · cited 4×
“[20] conducted a study on a group of 678 patients.”
BackgroundResultInfluentialYang, C.-Y., Lin, M.-W., Chang, Y.-L., Wu, C.-T., & Yang, P.-C. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.018 · Cited by 285
STAT3, stem cells, cancer stem cells and p63
Galoczova, M., Coates, P., & Vojtesek, B. (2018) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-018-0078-0 · Cited by 269
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
Wang, A., Wang, H. Y., Liu, Y., Zhao, M. C., Zhang, H. J., Lu, Z. Y., Fang, Y. C., Chen, X. F., & Liu, G. T. (2015) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2015.01.020 · Cited by 255
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
Schmidt, L. H., Kümmel, A., Görlich, D., Mohr, M., Bröckling, S., Mikesch, J. H., Grünewald, I., Marra, A., Schultheis, A. M., Wardelmann, E., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136023 · Cited by 231 · cited 1×
“In our cohort, involving a Western population, the incidence was lower, which is similar to other studies on this ethnic group [12,16,24] Another explanation for diverse expression of PD-L1 in NSCLC may be related to the use of different scoring methods and cut-off levels for evaluation.”
ResultPD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
Zhang, M., Li, G., Wang, Y., Wang, Y., Zhao, S., Haihong, P., Zhao, H., & Wang, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-10925-7 · Cited by 227
Kim, M.-Y., Koh, J., Kim, S., Go, H., Jeon, Y. K., & Chung, D. H. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.016 · Cited by 186
Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
Boland, J. M., Kwon, E. D., Harrington, S. M., Wampfler, J. A., Tang, H., Yang, P., & Aubry, M. C. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.05.006 · Cited by 185
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma
Takada, K., Okamoto, T., Shoji, F., Shimokawa, M., Akamine, T., Takamori, S., Katsura, M., Suzuki, Y., Fujishita, T., Toyokawa, G., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.006 · Cited by 183 · cited 1×
“[35] presented a positive mean correlation of the expression level of Ki-67 antigen and PD-L1 protein.”
BackgroundClinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
Shimoji, M., Shimizu, S., Sato, K., Suda, K., Kobayashi, Y., Tomizawa, K., Takemoto, T., & Mitsudomi, T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.021 · Cited by 158 · cited 7×
“It is believed that PD-L1 expression allows cancer cells to avoid the immune response [6].”
BackgroundResultInfluentialParra, E. R., Villalobos, P., Mino, B., & Rodriguez-Canales, J. (2018) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000531 · Cited by 155 · cited 4×
“The expression of PD-L1 in macrophages and lymphocytes is typical and was also observed in other studies [5].”
BackgroundResultInfluentialSun, J., Zhou, W., Choi, Y., Choi, S., Kim, S. E., Wang, Z., Dolled-Filhart, M. P., Emancipator, K., Wu, D., WEINER, R. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.007 · Cited by 153
Pan, Z., Ye, F., Wu, X., An, H., & Wu, J. (2015) · PubMed · doi:10.3978/j.issn.2072-1439.2015.02.13 · Cited by 141
Mao, Y., Li, W., Chen, K., Xie, Y., Liu, Q., Yao, M., Duan, W., Zhou, X., Liang, R., & Tao, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3097 · Cited by 123
Scholzen, T., Endl, E., Wohlenberg, C., van der Sar, S., Cowell, I. G., Gerdes, J., & Singh, P. B. (2002) · The Journal of Pathology · doi:10.1002/path.1016 · Cited by 115
Mino-Kenudson, M. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0009 · Cited by 103 · cited 5×
“High expression of PD-L1 in SCC was also observed by other authors [4,6,12,38,39].”
BackgroundResultInfluentialThe Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
Ribas, A., & Tumeh, P. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0933 · Cited by 97
Perea, F., Sánchez‐Palencia, A., Gómez‐Morales, M., Bernal, M., Concha, Á., García, M. M., Ramírez, A. R. G., Kerick, M., Martin, J. J., Garrido, F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23469 · Cited by 97 · cited 3×
“[36] examined the expression of PD-L1 and human leukocyte antigens-1 (HLA-I) in NSCLC and its association with TILs.”
BackgroundInfluentialLin, G., Fan, X., Zhu, W., Huang, C., Zhuang, W., Xu, H., Lin, X., Hu, D., Huang, Y., Jiang, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20233 · Cited by 95 · cited 4×
“Their roles in the first- or second-line treatment of advanced stages of NSCLC are well established, but the association between PD-L1 expression and clinicopathological features is still unclear and discussed in the literature [4].”
BackgroundMethodResultInfluentialIgarashi, T., Teramoto, K., Ishida, M., Hanaoka, J., & Daigo, Y. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000083 · Cited by 81 · cited 2×
“[29] also observed higher expression of PD-L1 in G2 and G3 in AC compared to G1 in AC.”
BackgroundResultEndl, E., Kausch, I., Baack, M., Knippers, R., Gerdes, J., & Scholzen, T. E. (2001) · The Journal of Pathology · doi:10.1002/path.978 · Cited by 80
PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.
Zhou, Z., Zhan, P., & Song, Y. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.03.02 · Cited by 77
The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma
Takada, K., Okamoto, T., Toyokawa, G., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Takamori, S., Katsura, M., Shoji, F., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.12.006 · Cited by 73 · cited 1×
“However, some authors emphasized significantly shorter survival in the SCC group [40].”
BackgroundZhou, F., Jiang, T., Ma, W., Gao, G., Chen, X., & Zhou, C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.005 · Cited by 69
Dzięgiel, P., Salwa-Zurawska, W., Żurawski, J., Wojnar, A., & Zabel, M. (2005) · PubMed · doi:10.14670/hh-20.83 · Cited by 60 · cited 1×
“The intensity of TTF-1, p63 and Ki-67 expression was determined with the use of a five-point scale (0—no expression, 1 point—1%–10%, 2 points—11%–25%, 3 points—26%–50%, 4 points >50%) [45].”
MethodPD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer
Zhou, C., Tang, J., Sun, H., Zheng, X., Li, Z., Sun, T., Li, J., Wang, S., Zhou, X., Sun, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17022 · Cited by 56 · cited 3×
“High expression of PD-L1 in SCC was also observed by other authors [4,6,12,38,39].”
BackgroundResultLi, B., Huang, X., & Fu, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s156421 · Cited by 54 · cited 2×
“[30] conducted a meta-analysis in 1981 of patients with NSCLC.”
BackgroundMethodShi, X., Wu, S., Sun, J. H., Liu, Y., Zeng, X., & Liang, Z. (2017) · Scientific Reports · doi:10.1038/srep46209 · Cited by 50 · cited 1×
“The connection of PD-1 with PD-L1 prevents an autoimmune response in peripheral tissues during inflammation [7].”
BackgroundKametaka, A., Takagi, M., Hayakawa, T., Haraguchi, T., Hiraoka, Y., & Yoneda, Y. (2002) · Genes to Cells · doi:10.1046/j.1365-2443.2002.00596.x · Cited by 44
Chen, Y., Liu-bo, W., Zhu, H., Li, X., Zhu, Y., Yin, Y., Lü, F.-Z., Wang, Z., & Qu, J. (2013) · Chinese Medical Sciences Journal · doi:10.1016/s1001-9294(13)60040-1 · Cited by 42
Zhong, A., Xing, Y., Pan, X., Shi, M., & Xu, H. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s91469 · Cited by 35
Kim, H., Kwon, H. J., Park, S. Y., Park, Y., Park, E., & Chung, J.-H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198634 · Cited by 34 · cited 2×
“, cell-blocks or core needle biopsy) may not be representative of the whole tumor issue [11,29].”
BackgroundResultSoubani, A. O., KANITKAR, A. A., Schwartz, A. G., & George, J. (2018) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_243_17 · Cited by 30 · cited 2×
“Early diagnosis and the use of the latest targeted therapies have contributed to a slight improvement in prognosis in patients even in advanced stages of the disease [2].”
BackgroundGlatzel-Plucinska, N. M., Piotrowska, A., Grzegrzółka, J., Olbromski, M., Rzechonek, A., Dzięgiel, P., & Podhorska‐Okołów, M. (2018) · Anticancer Research · doi:10.21873/anticanres.12278 · Cited by 19 · cited 1×
“This group includes mainly squamous cell carcinoma (SCC) and adenocarcinoma (AC) [3].”
BackgroundHerbst, R. S., Baas, P., Perez‐Gracia, J. L., Felip, E., Kim, D., Han, J., Molina, J. R., Kim, J.-H., Arvis, C. D., Ahn, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.112 · Cited by 8
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Guven, D. C., Sahin, T. K., Erul, E., Rizzo, A., Ricci, A. D., Aksoy, S., & Yalcin, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1039121 · Cited by 214
“Other than PD-L1 expression in non-small cell lung cancer (Pawelczyk et al., 2019), gastric cancer (Fuchs et al.”
BackgroundZhou, C., Wei, W.-F., Ma, J., Yang, Y., Liang, L.-J., Zhang, Y., Wang, Z., Chen, X., Huang, L., Wang, W., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.034 · Cited by 158
Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
Šutić, M., Vukić, A., Baranašić, J., Försti, A., Džubur, F., Samaržija, M., Jakopović, M., Brčić, L., & Knežević, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111102 · Cited by 150
Galvano, A., Gristina, V., Malapelle, U., Pisapia, P., Pepe, F., Barraco, N., Castiglia, M., Perez, A., Rolfo, C. D., Troncone, G., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100124 · Cited by 144
“Nonetheless, the clinical utility of TMB as a biomarker together with PD-L1 evaluation remains an enigma further complicated by the variety of measuring assays and algorithms.(15-19) Interestingly, no significant association between PD-L1 expression and TMB has been observed,(20) even when comparing the results obtain…”
Result
Metadata
- Authors
- Pawelczyk, K., Piotrowska, A., Ciesielska, U., Jablonska, K., Glatzel-Plucinska, N., Grzegrzolka, J., Podhorska-Okolow, M., Dziegiel, P., & Nowinska, K.
- Affiliations
- Department of Thoracic Surgery, Wroclaw Medical University, Wroclaw 53-439, Poland
- Wroclaw Medical University (PL)
- Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw 50-368, Poland
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-02-14
- Volume
- 20
- Issue
- 4
- Pages
- 824
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6413136
- OpenAlex
- W2913496992
- Cited by
- 192
- References
- 50
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 39 · 2023: 29 · 2022: 35 · 2021: 37 · 2020: 22 · 2019: 6
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu (ST.A110.17.037)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- PD-L1, non-small cell lung cancer, prognostic factors, tumor grade, lymph node metastasis, overall survival, lung adenocarcinoma, Ki-67, p63, TTF-1, PD-1/PD-L1 immune checkpoint, tumor cell proliferation
- MeSH terms
- Thyroid Nuclear Factor 1, Adenocarcinoma, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Male, Membrane Proteins, Middle Aged, Prognosis, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Ki-67 Antigen, Tissue Array Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.